Abstract
Objectives Prior studies have shown an anticancer effect of statins in patients with certain malignancies. However, it is unclear whether statins have a mortality benefit in lung cancer. We compared survival of patients with stage IV non-small cell lung cancer (NSCLC) receiving vs. not receiving statins prior to diagnosis. Methods Using data from the Surveillance, Epidemiology and End Results registry linked to Medicare claims, we identified 5118 patients >65 years of age diagnosed with stage IV NSCLC between 2007 and 2009. We used propensity score methods to assess the association of statin use with overall and lung cancer-specific survival while controlling for measured confounders. Results Overall, 27% of patients were on statins at time of lung cancer diagnosis. Median survival in the statin group was 7 months, compared to 4 months in patients not treated with statins (p < 0.001). Propensity score analyses found that statin use was associated with improvement in overall (hazard ratio [HR]: 0.76, 95% confidence interval [CI]: 0.73–0.79) and lung cancer-specific survival (HR: 0.77, 95% CI: 0.73–0.81), after controlling for baseline patient characteristics, cancer characteristics, staging work-up and chemotherapy use. Conclusions Statin use is associated with improved survival among patients with stage IV NSCLC suggesting a potential anticancer effect. Further research should evaluate plausible biological mechanisms as well as test the effect of statins in prospective clinical trials.
Original language | English |
---|---|
Pages (from-to) | 137-142 |
Number of pages | 6 |
Journal | Lung Cancer |
Volume | 99 |
DOIs | |
State | Published - 1 Sep 2016 |
Keywords
- Non-small cell lung cancer
- Outcomes
- Statins
- Survival analysis